Health ❯ Healthcare

Autoimmune Diseases

Lupus Rheumatoid Arthritis Systemic Lupus Erythematosus Psoriasis Research Dermatomyositis Multiple Sclerosis Neurological Disorders Disease Confirmation Treatment

Single CAR-T Infusion Puts Three Severe Autoimmune Diseases in Remission

The case signals a possible immune reset for B‑cell diseases pending larger, longer studies.

FDA Flags 76 Liver Injuries Linked to Amgen’s Tavneos, Urges Tight Monitoring

NEJM Publication Confirms Phase 3 Win for Brepocitinib in Dermatomyositis

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

UCSF-Led Study Engineers CAR-T Cells In Vivo, Clearing Tumors in Mice

MHRA Approves Leqselvi for Severe Alopecia Areata in Adults

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

YSRCP Renews Push for TTD Chief B.R. Naidu to Quit After Viral Videos

FDA Grants Breakthrough Therapy Designation to Biogen’s Litifilimab for Cutaneous Lupus

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

FDA Grants Priority Review to Vera's Atacicept for IgA Nephropathy

Zenas' Obexelimab Meets Phase 3 Goals in IgG4-Related Disease With 56% Flare Risk Cut

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Kyverna CAR-T Delivers Positive Phase 2 Topline in Stiff Person Syndrome as Shares Jump

Ianalumab Plus Eltrombopag Extends Disease Control in Phase 3 ITP Study Published in NEJM

Study Pinpoints GPR25 as Switch for Tissue-Resident Memory T Cell Formation

Off-Grid Trip Ends With Nobel Call for Immunologist Fred Ramsdell

Zenas BioPharma Licenses InnoCare’s Orelabrutinib in Autoimmune Deal Topping $2 Billion

Baricitinib's Type 1 Diabetes Gains Fade After Stopping in Two-Year Follow-Up

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing